AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34310866 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin (AZI)
Number of subjects: 180
Study 33731648 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercised (treadmill exercise session at the beginning of the fast)
Number of subjects: 20
Study 33731648 — intervention group
Group type: COMPARATOR
Intervention: Nonexercised (no treadmill exercise session at the beginning of the fast)
Number of subjects: 20
Study 33731648 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercised
Number of subjects: 20
Study 33731648 — intervention group
Group type: COMPARATOR
Intervention: Nonexercised
Number of subjects: 20
Study 33321849 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-coaching group (TC)
Number of subjects: 103
Study 33321849 — intervention group
Group type: COMPARATOR
Intervention: Control group without telephone-coaching (noTC)
Number of subjects: 103
Study 35940841 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription digital therapeutic (PDT) for mobile-delivered CBT-I (Somryst)
Number of subjects: 100
Study 35940841 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 100
Study 34362786 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxadustat
Number of subjects: 4277
Study 34362786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4277
Study 34658285 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered acupressure and exercise
Number of subjects: 221
Study 34658285 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of acupressure and exercise
Number of subjects: 221
Study 34887180 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (group D)
Number of subjects: 70
Study 34887180 — intervention group
Group type: COMPARATOR
Intervention: Propofol (group P)
Number of subjects: 70
Study 34887180 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study 33041146 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium
Number of subjects: 157
Study 33041146 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 157
Study 33041146 — intervention group
Group type: EXPERIMENTAL
Intervention: Prochlorperazine
Number of subjects: 157
Study 33041146 — intervention group
Group type: COMPARATOR
Intervention: Magnesium, Metoclopramide, Prochlorperazine
Number of subjects: 157
Study 33902763 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise + hot drink (60°C)
Number of subjects: 12
Study 33902763 — intervention group
Group type: COMPARATOR
Intervention: Exercise + cold drink (2°C)
Number of subjects: 12
Study 33902763 — intervention group
Group type: COMPARATOR
Intervention: Exercise (no preload)
Number of subjects: 12
Study 33724592 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized extract of Opuntia ficus-indica (400 mg/day) for 8 weeks
Number of subjects: 100
Study 33724592 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 32078062 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation (180 J) with infrared (IR 940 ± 10 nm)
Number of subjects: 48
Study 32078062 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation (180 J) with mixed Red and IR (RED/IR 620 + 940 nm)
Number of subjects: 48
Study 32078062 — intervention group
Group type: COMPARATOR
Intervention: Sham (disabled device)
Number of subjects: 48
Study 35729664 — intervention group
Group type: EXPERIMENTAL
Intervention: Media Aware (asynchronous, web‐based media literacy education program)
Number of subjects: 2010
Study 35729664 — intervention group
Group type: COMPARATOR
Intervention: Active control (sexual health education from Media Aware without MLE content or methods)
Number of subjects: 2010
Study 35729664 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention control group
Number of subjects: 2010
Study 32054535 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention including targeted health education, improved hospital CS policy, and training of midwives/doulas for 8 months.
Number of subjects: 21273
Study 32054535 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care).
Number of subjects: 21273
Study 32054535 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control).
Number of subjects: 21273
Study 33813917 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 positive patients
Number of subjects: 486
Study 32301137 — intervention group
Group type: EXPERIMENTAL
Intervention: Relamorelin 10 µg once or twice daily
Number of subjects: 597
Study 32301137 — intervention group
Group type: EXPERIMENTAL
Intervention: Relamorelin 10, 30 or 100 µg
Number of subjects: 597
Study 32301137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 597
Study 36293723 — intervention group
Group type: EXPERIMENTAL
Intervention: Curved environment
Number of subjects: 40
Study 36293723 — intervention group
Group type: COMPARATOR
Intervention: Linear environment
Number of subjects: 40
Study 34351939 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg daily
Number of subjects: 250
Study 34351939 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (initiate amlodipine only if hypertension develops)
Number of subjects: 250
Study 34351939 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehypertension treatment
Number of subjects: 250
Study 34351939 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 250
Study 85049646 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg daily for 5 days
Number of subjects: 0
Study 85049646 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg daily for 15 days
Number of subjects: 0
Study 85049646 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg daily for 25 days
Number of subjects: 0
Study 85049646 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 35513777 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation program with a motivational interview consisting of four motivational interviews and visits with family physicians, primary healthcare nurses, and a cardiologist.
Number of subjects: 284
Study 35513777 — intervention group
Group type: COMPARATOR
Intervention: Standard primary healthcare (control group).
Number of subjects: 284
Study 32869151 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron (50 mg once daily)
Number of subjects: 92
Study 32869151 — intervention group
Group type: COMPARATOR
Intervention: Solifenacin (5 mg once daily)
Number of subjects: 92
Study 32869151 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron
Number of subjects: 92
Study 32869151 — intervention group
Group type: COMPARATOR
Intervention: Solifenacin
Number of subjects: 92
Study 35370486 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (nonselective β-antagonist) administered for 1 week prior to and 4 weeks following HCT
Number of subjects: 25
Study 35370486 — intervention group
Group type: COMPARATOR
Intervention: Control group (no propranolol treatment)
Number of subjects: 25
Study 33715235 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut Oral Food Challenge (OFC)
Number of subjects: 121
Study 33715235 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of a light meal 1 h after reaction
Number of subjects: 121
Study 33715235 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic postural fall in blood pressure noted in preparation for discharge
Number of subjects: 121
Study 616389131 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-port retroperitoneal laparoscopy
Number of subjects: 80
Study 616389131 — intervention group
Group type: COMPARATOR
Intervention: Traditional three-port retroperitoneal laparoscopic surgery
Number of subjects: 80
Study 35162896 — intervention group
Group type: EXPERIMENTAL
Intervention: Active posters
Number of subjects: 175
Study 35162896 — intervention group
Group type: COMPARATOR
Intervention: Nature posters
Number of subjects: 175
Study 33953221 — intervention group
Group type: EXPERIMENTAL
Intervention: High Nitrogen (HN)
Number of subjects: 202
Study 33953221 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Nitrogen (LN)
Number of subjects: 202
Study 32406987 — intervention group
Group type: EXPERIMENTAL
Intervention: Child mouthing of soil
Number of subjects: 553
Study 32406987 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of animals in sleeping space
Number of subjects: 553
Study 35341657 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother-sung lullabies
Number of subjects: 60
Study 35341657 — intervention group
Group type: COMPARATOR
Intervention: Control group (no lullabies)
Number of subjects: 60
Study 33388444 — intervention group
Group type: EXPERIMENTAL
Intervention: Etonogestrel subdermal contraceptive implant (SCI)
Number of subjects: 540
Study 32378724 — intervention group
Group type: EXPERIMENTAL
Intervention: Herring roe oil supplementation
Number of subjects: 64
Study 32378724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 33300296 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 5929
Study 33300296 — intervention group
Group type: COMPARATOR
Intervention: Syntometrine
Number of subjects: 5929
Study 33300296 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbetocin
Number of subjects: 5929
Study 35348764 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypharmacy (≥5 medications)
Number of subjects: 718
Study 35348764 — intervention group
Group type: EXPERIMENTAL
Intervention: Excessive polypharmacy (≥10 medications)
Number of subjects: 718
Study 35348764 — intervention group
Group type: EXPERIMENTAL
Intervention: Potentially inappropriate medications (PIM)
Number of subjects: 718
Study 35348764 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular medications
Number of subjects: 718
Study 35348764 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonprescription medications
Number of subjects: 718
Study 35348764 — intervention group
Group type: EXPERIMENTAL
Intervention: Potential major drug-drug interactions (DDI)
Number of subjects: 718
Study 35348764 — intervention group
Group type: EXPERIMENTAL
Intervention: Potential major drug-cancer treatment interactions (DCI)
Number of subjects: 718
Study 35348764 — intervention group
Group type: EXPERIMENTAL
Intervention: Each additional medication
Number of subjects: 718
Study 32151439 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional e-mail counseling
Number of subjects: 200
Study 32151439 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led Web discussion
Number of subjects: 200
Study 32151439 — intervention group
Group type: COMPARATOR
Intervention: Interpersonal support
Number of subjects: 200
Study 36284645 — intervention group
Group type: EXPERIMENTAL
Intervention: Favipiravir 1800 mg on day 1, then 800 mg twice daily for 14 days
Number of subjects: 200
Study 36284645 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 200
Study 36284645 — intervention group
Group type: EXPERIMENTAL
Intervention: Favipiravir
Number of subjects: 200
Study 36284645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 33075200 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulation behaviour change techniques (BCTs)
Number of subjects: 12
Study 35419334 — intervention group
Group type: EXPERIMENTAL
Intervention: Flipped Classroom (FC) teaching
Number of subjects: 119
Study 35419334 — intervention group
Group type: COMPARATOR
Intervention: Traditional Lecture (TL) teaching
Number of subjects: 119
Study 32439189 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nitroglycerin patch (5 mg) applied 1 hour before anesthesia
Number of subjects: 40
Study 32439189 — intervention group
Group type: COMPARATOR
Intervention: Control group with gauze pad applied to bare skin
Number of subjects: 40
Study 32439189 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nitroglycerin patch (5 mg)
Number of subjects: 40
Study 34864695 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal stimulation (MMS) for 5 days, 30 minutes/session, totaling five sessions
Number of subjects: 32
Study 34864695 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 32
Study 34392585 — intervention group
Group type: EXPERIMENTAL
Intervention: Various land-use histories
Number of subjects: 4000
Study 34392585 — intervention group
Group type: EXPERIMENTAL
Intervention: Local space-for-time comparisons
Number of subjects: 4000
Study 34392585 — intervention group
Group type: EXPERIMENTAL
Intervention: Research in temperate forested biomes
Number of subjects: 4000
Study 34392585 — intervention group
Group type: EXPERIMENTAL
Intervention: Research priorities and data gaps
Number of subjects: 4000
Study 32356581 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (BVB) 1.25 mg
Number of subjects: 61
Study 32356581 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone acetonide (TCA) 4 mg
Number of subjects: 61
Study 36273203 — intervention group
Group type: COMPARATOR
Intervention: Current standard-of-care anticoagulation practice
Number of subjects: 15000
Study 36273203 — intervention group
Group type: EXPERIMENTAL
Intervention: HA-VTE risk probability calculated from a validated VTE risk-prediction model with daily updates and additional review by hematologists for patients with elevated risk (predicted probability of HA-VTE ≥ 0.025)
Number of subjects: 15000
Study 34214614 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal boost to external beam radiotherapy (EBRT)
Number of subjects: 0
Study 34214614 — intervention group
Group type: COMPARATOR
Intervention: External beam radiotherapy (EBRT) without focal boost
Number of subjects: 0
Study 35065008 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-step support strategy (physician-driven, nurse-aided) including family conference, ICU-room visit, and post-death meeting.
Number of subjects: 875
Study 35065008 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 875
Study 33741550 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening by clinical breast examination
Number of subjects: 0
Study 33741550 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 32589630 — intervention group
Group type: EXPERIMENTAL
Intervention: Vienna Prediction Model (VPM) guided anticoagulant treatment
Number of subjects: 883
Study 32589630 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 883
Study 35783617 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation combined with auricular acupressure
Number of subjects: 210
Study 35783617 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 210
Study 33275596 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted alcohol consumption
Number of subjects: 1200000
Study 33275596 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted smoking
Number of subjects: 1200000
Study 36097826 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates
Number of subjects: 98
Study 36097826 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise
Number of subjects: 98
Study 33336888 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose glucagon (150 μg subcutaneous)
Number of subjects: 10
Study 33221955 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan 20 mg
Number of subjects: 73
Study 33221955 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan 10 mg
Number of subjects: 73
Study 35112582 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative video
Number of subjects: 500
Study 35112582 — intervention group
Group type: COMPARATOR
Intervention: Flipchart presentation
Number of subjects: 500
Study 35112582 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (video and flipchart)
Number of subjects: 500
Study 33521870 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing alone (SRP alone)
Number of subjects: 44
Study 33521870 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing with diode laser (SRP + DL)
Number of subjects: 44
Study 33032658 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharibacteria
Number of subjects: 1475
Study 33032658 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation
Number of subjects: 1475
Study 33032658 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic kidney disease
Number of subjects: 1475
Study 33032658 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate cancer
Number of subjects: 1475
Study 33032658 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic lupus erythematosus and chronic myeloid leukaemia
Number of subjects: 1475
Study 35048770 — intervention group
Group type: EXPERIMENTAL
Intervention: Anabolic steroids, physiotherapy, and nutritional supplement
Number of subjects: 19
Study 35048770 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised outpatient rehabilitation with individually structured progressive strength training
Number of subjects: 19
Study 33245144 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile technology intervention (unidirectional text message reminders)
Number of subjects: 220
Study 33245144 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mobile technology intervention)
Number of subjects: 220
Study 35040594 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily nasal irrigation with Johnson and Johnson's Baby Shampoo (J&J) in hypertonic saline
Number of subjects: 72
Study 35040594 — intervention group
Group type: COMPARATOR
Intervention: Hypertonic saline alone
Number of subjects: 72
Study 35040594 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 72
Study 33400436 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical morphine (10 mg) with intrasite gel
Number of subjects: 0
Study 33400436 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical loperamide (dose not specified) with intrasite gel
Number of subjects: 0
Study 35147085 — intervention group
Group type: EXPERIMENTAL
Intervention: Target-controlled plasma infusion of lidocaine (3 mg/L) during induction and maintenance of anesthesia
Number of subjects: 80
Study 35147085 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (control group)
Number of subjects: 80
Study 34726026 — intervention group
Group type: EXPERIMENTAL
Intervention: Qiang Jin exercises, performed one time each morning and evening, 10 sets each time for 12 weeks.
Number of subjects: 98
Study 34726026 — intervention group
Group type: COMPARATOR
Intervention: Classic rehabilitation training, performed twice a week for 12 weeks.
Number of subjects: 98
Study 35866633 — intervention group
Group type: EXPERIMENTAL
Intervention: Marburg virus vaccine candidates
Number of subjects: 20000
Study 35866633 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 20000
Study 33280990 — intervention group
Group type: COMPARATOR
Intervention: Standard screws
Number of subjects: 10
Study 33280990 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide-head screws
Number of subjects: 10
Study 35583217 — intervention group
Group type: EXPERIMENTAL
Intervention: Turner syndrome patients (TS)
Number of subjects: 70
Study 35583217 — intervention group
Group type: EXPERIMENTAL
Intervention: Turner syndrome patients (TS) with orthodontic treatment
Number of subjects: 70
Study 35583217 — intervention group
Group type: COMPARATOR
Intervention: Control group (girls without TS)
Number of subjects: 70
Study 34813098 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep breathing treatment video
Number of subjects: 342
Study 34813098 — intervention group
Group type: COMPARATOR
Intervention: Control group (informational video)
Number of subjects: 342
Study 33010325 — intervention group
Group type: EXPERIMENTAL
Intervention: Omiganan 2.5%
Number of subjects: 80
Study 33010325 — intervention group
Group type: EXPERIMENTAL
Intervention: Omiganan 1% and 1.75%
Number of subjects: 80
Study 33010325 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 80
Study 34324798 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive psychology-motivational interviewing (PP-MI) intervention, delivered over 12 weeks via phone.
Number of subjects: 11
Study 36446460 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi-atrial ablation
Number of subjects: 320
Study 36446460 — intervention group
Group type: COMPARATOR
Intervention: Left atrial ablation
Number of subjects: 320
Study 33210302 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose tocilizumab (40 to 200 mg, with allowance for one repeat dose at 24 to 48 hours)
Number of subjects: 32
Study 35279081 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-based therapy with amikacin liposome inhalation suspension
Number of subjects: 71
Study 35279081 — intervention group
Group type: COMPARATOR
Intervention: Guideline-based therapy without amikacin liposome inhalation suspension
Number of subjects: 71
Study 33487590 — intervention group
Group type: EXPERIMENTAL
Intervention: Farm-to-WIC intervention promoting vegetable intake
Number of subjects: 297
Study 33487590 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 297
Study 35752527 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 0
Study 35752527 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 0
Study 34933416 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy (testosterone undecanoate injection three times/6 months, n=20)
Number of subjects: 41
Study 34933416 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections (n=21)
Number of subjects: 41
Study 34933416 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy
Number of subjects: 41
Study 34933416 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 41
Study 33862636 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection of pulmonary metastases of urothelium carcinoma
Number of subjects: 139
Study 33862636 — intervention group
Group type: EXPERIMENTAL
Intervention: Univariate analysis of relapse-free interval
Number of subjects: 139
Study 32764524 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention group
Number of subjects: 196
Study 32764524 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 196
Study 36054449 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial alteplase (0.225mg/kg)
Number of subjects: 36